title: Time for a level playing field: inequalities in regulatory/approval processes—the example of bevacizumab in epithelial ovarian cancer.
authors.affiliation: British Columbia Cancer Agency, Vancouver, British Columbia, Canada phoskins@bccancer.bc.ca.
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Hoskins
authors.affiliation: University of Ottawa, Ottawa, Ontario, Canada.
authors.forename: Michael
authors.initials: M
authors.lastname: Fung-Kee-Fung
authors.affiliation: Columbia Cancer Agency, Vancouver, British Columbia, Canada.
authors.forename: Dianne
authors.initials: D
authors.lastname: Miller
authors.affiliation: McGill University, Montreal, Quebec, Canada.
authors.forename: Walter
authors.initials: W
authors.lastname: Gotlieb
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000191:economics* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy / Q000191:economics; D002170:Canada; D000077216:Carcinoma, Ovarian Epithelial; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000191:economics; D003362:Cost-Benefit Analysis; D018572:Disease-Free Survival; D017277:Drug Approval; D016527:Drug Costs; D005062:European Union; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000191:economics; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy / Q000191:economics; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000191:economics; D011057:Politics; D012008:Recurrence; D016019:Survival Analysis; D016896:Treatment Outcome; D006113:United Kingdom; D014481:United States; D014486:United States Food and Drug Administration; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab